Nuclear and mitochondrial changes of muscle fibers in AIDS after treatment with high doses of zidovudine
- PMID: 1285495
- DOI: 10.1007/BF00304632
Nuclear and mitochondrial changes of muscle fibers in AIDS after treatment with high doses of zidovudine
Abstract
Zidovudine (formerly azidothymidine) is a potent inhibitor of the human immunodeficiency virus (HIV) reverse transcriptase and represents the first approved drug showing clinical efficacy in HIV-associated diseases. However, considerable toxicity causing macrocytic anemia, neutropenia, and myopathy has been reported, with severe mitochondrial alterations as a special feature of this myopathy. The mitochondrial changes are consistent with the fact that zidovudine acts as an inhibitor of the mitochondrial gamma-polymerase. Electron microscopically, we could confirm the presence of severely altered mitochondria in a 32-year-old male, who developed a necrotizing myopathy after daily administration of 1,000 mg zidovudine over a period of 15 months. In addition, there were even more severe nuclear changes that, for the most part, have not been documented electron microscopically in HIV-related myopathy either with or without zidovudine treatment, especially in non-necrotic and non-regenerating fibers. Since various in vitro studies have shown interference of zidovudine with nuclear DNA metabolism even in human cell lines, we assume that the nuclear changes that we observed are at least in part related to zidovudine treatment.
Similar articles
-
Mitochondrial myopathy caused by long-term zidovudine therapy.N Engl J Med. 1990 Apr 19;322(16):1098-105. doi: 10.1056/NEJM199004193221602. N Engl J Med. 1990. PMID: 2320079
-
Major growth reduction and minor decrease in mitochondrial enzyme activity in cultured human muscle cells after exposure to zidovudine.Muscle Nerve. 1992 Jun;15(6):706-10. doi: 10.1002/mus.880150613. Muscle Nerve. 1992. PMID: 1324428
-
Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy.Ann Neurol. 1993 Aug;34(2):206-11. doi: 10.1002/ana.410340217. Ann Neurol. 1993. PMID: 8338345
-
Skeletal muscle involvement in HIV-infected patients.Neuropathol Appl Neurobiol. 1994 Jun;20(3):232-7. doi: 10.1111/j.1365-2990.1994.tb00964.x. Neuropathol Appl Neurobiol. 1994. PMID: 7936072 Review.
-
[Muscular complications in HIV infection].Arch Anat Cytol Pathol. 1997;45(2-3):174-8. Arch Anat Cytol Pathol. 1997. PMID: 9382610 Review. French.
Cited by
-
Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations.Acta Neuropathol. 1995;90(1):1-6. doi: 10.1007/BF00294452. Acta Neuropathol. 1995. PMID: 7572071 Clinical Trial.
-
Schwann cell mitochondrial alterations in peripheral nerves of rabbits treated with 2',3'-dideoxycytidine.Acta Neuropathol. 1994;87(1):71-80. doi: 10.1007/BF00386256. Acta Neuropathol. 1994. PMID: 8140896
-
AZT-induced oxidative cardiovascular toxicity: attenuation by Mg-supplementation.Cardiovasc Toxicol. 2009 Jun;9(2):78-85. doi: 10.1007/s12012-009-9040-8. Epub 2009 May 12. Cardiovasc Toxicol. 2009. PMID: 19484392 Free PMC article.
-
Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.Drugs. 1993 Sep;46(3):515-578. doi: 10.2165/00003495-199346030-00010. Drugs. 1993. PMID: 7693435 Review.
-
Mitochondrial disruption and apoptosis in lymphocytes of an HIV infected patient affected by lactic acidosis after treatment with highly active antiretroviral therapy.J Clin Pathol. 2003 Feb;56(2):147-51. doi: 10.1136/jcp.56.2.147. J Clin Pathol. 2003. PMID: 12560398 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical